OKYO
$1.57-0.05 (-3.09%)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Recent News
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy urcosimod in a mid-stage study for neuropathic corneal pain (NCP), a chronic eye condition with no approved treatments. The clinical-stage...
Dow Jones sheds more than 800 points on Trump's latest tariff threat
4:15pm: Tariff fallout Trump’s new global tariffs saw US stocks finish the day firmly in the red. The Dow Jones fell 1.7% or about 820 points to 48,804 points, the Nasdaq was down 1.1% at 22,627 points and the S&P 500 fell 1% to 6,837 points. 3:30pm: Proactive news headlines OKYO...
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026...
Nasdaq posts slim gain in calm trade as Wall Street inches up
Wall Street is reopening after the long weekend with investors still grappling with the recent pullback in technology shares
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
Analysts from Lucid Capital, H.C. Wainwright, and B. Riley Securities have all repeated ‘Buy’ ratings on OKYO Pharma Ltd (NASDAQ:OKYO), highlighting the company’s promising urcosimod program and its potential to address an unmet need in neuropathic corneal pain (NCP). The positive sentiment...